Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation

(2013) Min Dai et al.   JOURNAL OF IMMUNOTHERAPY

Combinatorial PD-1 Blockade and CD137 Activation Has Therapeutic Efficacy in Murine Cancer Models and Synergizes with Cisplatin

(2013) Huafeng Wei et al.   PLoS One

Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies

(2012) I. Verbrugge et al.   CANCER RESEARCH

Immunotherapy in ovarian cancer

(2012) Gina M. Mantia-Smaldone et al.   Human Vaccines & Immunotherapeutics

Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer Immunotherapy

(2010) Chenghong Lei et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY